Role of Integrins in Resistance to Therapies Targeting Growth Factor Receptors in Cancer - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Cancers Année : 2019

Role of Integrins in Resistance to Therapies Targeting Growth Factor Receptors in Cancer

Résumé

Integrins contribute to cancer progression and aggressiveness by activating intracellular signal transduction pathways and transducing mechanical tension forces. Remarkably, these adhesion receptors share common signaling networks with receptor tyrosine kinases (RTKs) and support their oncogenic activity, thereby promoting cancer cell proliferation, survival and invasion. During the last decade, preclinical studies have revealed that integrins play an important role in resistance to therapies targeting RTKs and their downstream pathways. A remarkable feature of integrins is their wide-ranging interconnection with RTKs, which helps cancer cells to adapt and better survive therapeutic treatments. In this context, we should consider not only the integrins expressed in cancer cells but also those expressed in stromal cells, since these can mechanically increase the rigidity of the tumor microenvironment and confer resistance to treatment. This review presents some of these mechanisms and outlines new treatment options for improving the efficacy of therapies targeting RTK signaling.
Fichier principal
Vignette du fichier
cancers-11-00692.pdf (2.24 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Licence : CC BY - Paternité

Dates et versions

hal-02392746 , version 1 (26-06-2023)

Licence

Paternité

Identifiants

Citer

Elisabete Cruz da Silva, Monique Dontenwill, Laurence Choulier, Maxime Lehmann. Role of Integrins in Resistance to Therapies Targeting Growth Factor Receptors in Cancer. Cancers, 2019, 11 (5), pp.692. ⟨10.3390/cancers11050692⟩. ⟨hal-02392746⟩
23 Consultations
3 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More